CollPlant Biotechnologies Ltd. - Form 20-F Summary (Fiscal Year Ended December 31, 2025)
Business Context and Reporting Period
Company: CollPlant Biotechnologies Ltd. (Nasdaq: CLGN)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: CollPlant is a regenerative and aesthetic medicine company focused on medical aesthetics and 3D bioprinting. Its core technology involves producing recombinant human collagen (rhCollagen) using genetically engineered tobacco plants. Key product pipelines include dermal fillers (in collaboration with AbbVie), 3D-bioprinted breast implants, and bioinks for tissue engineering.
Listing Status: Ordinary shares trade on the Nasdaq Capital Market. The company is a "foreign private issuer" incorporated in Israel.
Key Financial Metrics
| Metric (USD in thousands) | 2025 | 2024 |
|---|---|---|
| Revenues | $2,371 | $515 |
| Cost of Revenues | $835 | $1,625 |
| Gross Profit | $1,536 | $(1,110) |
| Net Loss | $(11,489) | $(16,609) |
| Cash and Cash Equivalents (Year End) | $5,591 | $11,909 |
| Accumulated Deficit | $(124,839) | $(113,350) |
| Operating Cash Flow | $(9,419) | $(14,093) |
Note: The filing text does not provide a specific "profit margin" percentage due to the company's net loss status. Gross margin improved significantly in 2025 due to milestone revenue.
Material Changes vs. Prior Period
- Revenue Surge: Revenues increased 360% to $2.4 million, primarily driven by a $2 million milestone payment from AbbVie in February 2025 related to the dermal filler product candidate. In 2024, revenue was minimal ($0.5 million) as no major milestones were achieved.
- Reduced Net Loss: Net loss decreased to $11.5 million from $16.6 million in 2024. This improvement was driven by the milestone revenue and cost-cutting measures.
- Expense Reduction: Research and Development (R&D) expenses decreased by $2.3 million (to $8.2 million) and General, Administrative, and Marketing (G&A) expenses decreased by $0.8 million (to $4.8 million). These reductions resulted from workforce reductions (approximately 20% in Q1 2025 and an additional 27% in Q4 2025) and reduced material costs.
- Liquidity Decline: Cash and cash equivalents dropped by approximately $6.3 million year-over-year, reflecting continued negative operating cash flows despite the milestone payment.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: Management and the independent auditors (Kost Forer Gabbay & Kasierer) have expressed substantial doubt about the Company's ability to continue as a going concern. As of March 15, 2026, cash resources were approximately $4.3 million, which is insufficient to fund operations for the next 12 months. The company requires additional financing to continue operations.
Outlook and Milestones:
- AbbVie Collaboration: AbbVie is reviewing interim results from the first cohort of patients in the dermal filler clinical trials initiated in 2023. Future payments depend on these results and subsequent milestones.
- Product Pipeline: The company is advancing its photocurable dermal filler into clinical trials and optimizing 3D-bioprinted breast implants following positive preclinical data.
- Financing: The company completed a registered direct offering in June 2025 ($3.6 million gross proceeds) and another in February 2026 ($2.0 million gross proceeds) to bolster liquidity.
Key Risks:
- Capital Requirements: Failure to raise additional capital could force the company to delay or terminate product development.
- Geopolitical Instability: Operations are based in Israel. Ongoing conflicts (including hostilities with Hezbollah and Iran) pose risks to facilities, workforce availability, and supply chains. The Yessod Hama'ala facility was temporarily closed in 2024 due to proximity to the Lebanon border.
- Regulatory Approval: Success depends on obtaining regulatory approvals (FDA, CE Mark) for novel products, which is uncertain and costly.
- Nasdaq Compliance: The company received a notice from Nasdaq in March 2026 regarding non-compliance with the minimum bid price requirement ($1.00 per share). It has 180 days to regain compliance or face delisting.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2 million raised in February 2026 combined with existing cash to fund operations through the next 12 months.
- AbbVie Trial Status: Monitor announcements regarding the interim results of the dermal filler clinical trials, as future milestone payments hinge on this data.
- Nasdaq Compliance Plan: Review the company's strategy to regain compliance with the $1.00 minimum bid price rule (e.g., reverse stock split) to avoid delisting.
- Geopolitical Impact: Assess the current operational status of the Yessod Hama'ala production facility and any ongoing disruptions due to the security situation in Israel.
- IIA Obligations: Confirm the status of royalty payments to the Israeli Innovation Authority (IIA), which are tied to revenue and may impact net cash flow.